Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

ADRs lost ~15% in the premarket on Tuesday after the Danish drugmaker lowered its full-year outlook, citing, among other ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk announces a leadership transition as Lars Fruergaard Jørgensen welcomes new CEO Doug Doustdar. Doustdar aims to ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...